Actinium Pharmaceuticals Inc
ATNM
Get informed when a big investor buys or sells
+ FollowMarket Cap$36.71M
Close$
$1.48
23.5% upside
Current Fair Value
23.5% upsideUndervalued by 23.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.71 Million |
|---|---|
| Enterprise Value | $1.58 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 0.02 |
| Outstanding Shares | 31,399,086 |
Return
| Return on Equity | 37.32% |
|---|---|
| Return on Assets | 28.16% |
| Return on Invested Capital | 26.64% |
Valuation & Multiples
| P/E Ratio | 3.25 |
|---|---|
| PEG | -0.64 |
| Price to Sales | 1.2 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.04 |
| Enterprise Value to EBIT | 0.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.85 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$35.62 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.25
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 19,500▼ 84.71% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 16.85%▼ 0.12% |
|---|---|
| Total Invested | $5.18M▼ 1.70% |
| Investors Holding | 48▼ 7.00% |
ESG Score
No data
About Actinium Pharmaceuticals Inc
CEO: Sandesh Seth